Associations - Topoisomerase I inhibitor

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval Lancet - 1 week (New B) fam-trastuzumab deruxtecan-nxki Sensitive : A1 Lancet - 1wk	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval Lancet - 1 week fam-trastuzumab deruxtecan-nxki Sensitive : A1 Lancet - 1 week - (New B)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval ASCO 2023 - 1 week (New B) sacituzumab govitecan-hziy Sensitive : A1 ASCO 2023 - 1wk	sacituzumab govitecan-hziy Sensitive: A1 - Approval ASCO 2023 - 1 week sacituzumab govitecan-hziy Sensitive : A1 ASCO 2023 - 1 week - (New B)
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ASCO 2023 - 1 week (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : A1 ASCO 2023 - 1wk	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ASCO 2023 - 1 week fam-trastuzumab deruxtecan-nxki Sensitive : A1 ASCO 2023 - 1 week - (New C3)
HER-2 amplification	Colorectal Cancer	HER-2 amplification	Colorectal Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline ASCO 2023 - 1 week (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : A2 ASCO 2023 - 1wk	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline ASCO 2023 - 1 week fam-trastuzumab deruxtecan-nxki Sensitive : A2 ASCO 2023 - 1 week - (New C3)
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	pembrolizumab + DS-1062a Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) pembrolizumab + DS-1062a Sensitive : C3 ASCO 2023 - 1wk	pembrolizumab + DS-1062a Sensitive: C3 – Early Trials ASCO 2023 - 1 week pembrolizumab + DS-1062a Sensitive : C3 ASCO 2023 - 1 week - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab + DS-1062a Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) pembrolizumab + DS-1062a Sensitive : C3 ASCO 2023 - 1wk	pembrolizumab + DS-1062a Sensitive: C3 – Early Trials ASCO 2023 - 1 week pembrolizumab + DS-1062a Sensitive : C3 ASCO 2023 - 1 week - (New C3)
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	pembrolizumab + DS-1062a Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) pembrolizumab + DS-1062a Sensitive : C3 ASCO 2023 - 1wk	pembrolizumab + DS-1062a Sensitive: C3 – Early Trials ASCO 2023 - 1 week pembrolizumab + DS-1062a Sensitive : C3 ASCO 2023 - 1 week - (New C3)
TP53 mutation + MDM2 mutation	Urothelial Cancer	TP53 mutation + MDM2 mutation	Urothelial Cancer	sacituzumab govitecan-hziy Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) sacituzumab govitecan-hziy Sensitive : C3 ASCO 2023 - 1wk	sacituzumab govitecan-hziy Sensitive: C3 – Early Trials ASCO 2023 - 1 week sacituzumab govitecan-hziy Sensitive : C3 ASCO 2023 - 1 week - (New C3)
HER-2 underexpression + ER underexpression	Breast Cancer	HER-2 underexpression + ER underexpression	Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials ESMO-BC 2023 - 4 weeks (New B) fam-trastuzumab deruxtecan-nxki Sensitive : B ESMO-BC 2023 - 4wk	fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials ESMO-BC 2023 - 4 weeks fam-trastuzumab deruxtecan-nxki Sensitive : B ESMO-BC 2023 - 4 weeks - (New B)
HR positive + HER-2 underexpression	Breast Cancer	HR positive + HER-2 underexpression	Breast Cancer	U3-1402 Sensitive: C3 – Early Trials ESMO-BC 2023 - 4 weeks (New C3) U3-1402 Sensitive : C3 ESMO-BC 2023 - 4wk	U3-1402 Sensitive: C3 – Early Trials ESMO-BC 2023 - 4 weeks U3-1402 Sensitive : C3 ESMO-BC 2023 - 4 weeks - (New C3)
TROP2 overexpression	Breast Cancer	TROP2 overexpression	Breast Cancer	DS-1062a Sensitive: D – Preclinical ESMO-BC 2023 - 4 weeks (New D) DS-1062a Sensitive : D ESMO-BC 2023 - 4wk	DS-1062a Sensitive: D – Preclinical ESMO-BC 2023 - 4 weeks DS-1062a Sensitive : D ESMO-BC 2023 - 4 weeks - (New D)
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	topotecan Sensitive: A1 - Approval topotecan Sensitive : A1	topotecan Sensitive: A1 - Approval topotecan Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	topotecan Sensitive: A1 - Approval topotecan Sensitive : A1	topotecan Sensitive: A1 - Approval topotecan Sensitive : A1
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval leucovorin calcium + nanoliposomal irinotecan Sensitive : A1	leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval leucovorin calcium + nanoliposomal irinotecan Sensitive : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1
No biomarker	Triple Negative Breast Cancer	No biomarker	Triple Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	paclitaxel + topotecan Sensitive: A2 - Guideline paclitaxel + topotecan Sensitive : A2	paclitaxel + topotecan Sensitive: A2 - Guideline paclitaxel + topotecan Sensitive : A2
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	nanoliposomal irinotecan Sensitive: A2 - Guideline nanoliposomal irinotecan Sensitive : A2	nanoliposomal irinotecan Sensitive: A2 - Guideline nanoliposomal irinotecan Sensitive : A2
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	topotecan Sensitive: A2 - Guideline topotecan Sensitive : A2	topotecan Sensitive: A2 - Guideline topotecan Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	topotecan Sensitive: A2 - Guideline topotecan Sensitive : A2	topotecan Sensitive: A2 - Guideline topotecan Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	cisplatin + irinotecan Sensitive: A2 - Guideline cisplatin + irinotecan Sensitive : A2	cisplatin + irinotecan Sensitive: A2 - Guideline cisplatin + irinotecan Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2
No biomarker	Nasopharyngeal Carcinoma	No biomarker	Nasopharyngeal Carcinoma	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2
No biomarker	Penile Cancer	No biomarker	Penile Cancer	cisplatin + irinotecan Sensitive: A2 - Guideline cisplatin + irinotecan Sensitive : A2	cisplatin + irinotecan Sensitive: A2 - Guideline cisplatin + irinotecan Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	docetaxel + irinotecan Sensitive: A2 - Guideline docetaxel + irinotecan Sensitive : A2	docetaxel + irinotecan Sensitive: A2 - Guideline docetaxel + irinotecan Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2
No biomarker	Small Intestinal Carcinoma	No biomarker	Small Intestinal Carcinoma	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	topotecan Sensitive: A2 - Guideline topotecan Sensitive : A2	topotecan Sensitive: A2 - Guideline topotecan Sensitive : A2
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	topotecan Sensitive: A2 - Guideline topotecan Sensitive : A2	topotecan Sensitive: A2 - Guideline topotecan Sensitive : A2
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	cisplatin + irinotecan Sensitive: A2 - Guideline cisplatin + irinotecan Sensitive : A2	cisplatin + irinotecan Sensitive: A2 - Guideline cisplatin + irinotecan Sensitive : A2
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	docetaxel + irinotecan Sensitive: A2 - Guideline docetaxel + irinotecan Sensitive : A2	docetaxel + irinotecan Sensitive: A2 - Guideline docetaxel + irinotecan Sensitive : A2

Topoisomerase I inhibitor

Topoisomerase I inhibitor

Associations(220)

Associations
(220)